Skip to main content
SpringerLink
Log in

Nivolumab increases risk of arterial hypertension

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Calderon EC, et al. Cardiovascular Adverse Events Associated with Nivolumab Versus Standard Chemotherapy in Patients with Cancer. A Meta-Analysis of Ramdomized Control Trials. 70th Annual Scientific Session of the American College of Cardiology : 15 May 2021. Available from: URL: https://www.sciencedirect.com/science/article/pii/S0735109721046696

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nivolumab increases risk of arterial hypertension. Reactions Weekly 1863, 11 (2021). https://doi.org/10.1007/s40278-021-98615-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-98615-1

Search

Navigation